Skip to contentP
PharmaCyte Biotech, Inc.
P
PMCBPharmaCyte Biotech, Inc. Q1 2027 · 10-Q
Revenue$0.00$0.00— vs Q1 2026 Net Income-$5.08M-$5.08MN/M vs Q1 2026 EPS Diluted-$0.54-$0.54N/M vs Q1 2026 Operating Income-$1,006,708N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
PharmaCyte Biotech, Inc. · CIK 1157075 · Engraved from SEC EDGAR
ended Jul 31, 2026 · filed Sep 14, 2026 · 45 d after period end